Stay updated on DESTINY-B12 Clinical Trial

Sign up to get notified when there's something new on the DESTINY-B12 Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the DESTINY-B12 Clinical Trial page

  1. Check
    6 days ago
    No Change Detected
  2. Check
    13 days ago
    Change Detected
    Summary
    The expected modernization date for the ClinicalTrials.gov data ingest has been updated from June 2025 to July 2025.
    Difference
    0.4%
    Check dated 2025-06-19T19:39:43.000Z thumbnail image
  3. Check
    20 days ago
    No Change Detected
  4. Check
    27 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.16.1 to version 2.16.2.
    Difference
    0.0%
    Check dated 2025-06-05T11:14:29.000Z thumbnail image
  5. Check
    35 days ago
    Change Detected
    Summary
    The web page has been updated to indicate that the ClinicalTrials.gov data ingest will be modernized in June 2025, allowing API users to provide input before implementation. Additionally, the revision number has been updated from v2.15.2 to v2.16.1.
    Difference
    0.7%
    Check dated 2025-05-29T05:58:50.000Z thumbnail image
  6. Check
    42 days ago
    Change Detected
    Summary
    The webpage has been updated to include new clinical trial results and metrics related to the treatment of HER2-positive metastatic breast cancer, specifically focusing on participants with and without brain metastasis. Key metrics such as Objective Response Rate (ORR), Progression-Free Survival (PFS), and survival rates have been added, while previous data points have been removed.
    Difference
    76%
    Check dated 2025-05-22T02:37:22.000Z thumbnail image
  7. Check
    63 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.15.0 to version 2.15.2, indicating a revision in the content.
    Difference
    0.0%
    Check dated 2025-04-30T14:15:55.000Z thumbnail image
  8. Check
    77 days ago
    Change Detected
    Summary
    The webpage has undergone significant changes, including the removal of detailed study descriptions and eligibility criteria for a clinical trial on Trastuzumab deruxtecan, while adding new identifiers and collaborators related to breast cancer research.
    Difference
    24%
    Check dated 2025-04-16T08:06:51.000Z thumbnail image

Stay in the know with updates to DESTINY-B12 Clinical Trial

Enter your email address, and we'll notify you when there's something new on the DESTINY-B12 Clinical Trial page.